A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
NCT07946575
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The primary purpose of this study is to evaluate the effect of quinidine sulfate on the pharmacokinetics (PK) of NAL ER in healthy participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Participants
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Trevi Therapeutics
- Last updated on ClinicalTrials.gov
- November 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Clinical Pharmacology of Miami, LLC · Miami, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.